State co-funding agreement for orphan drug signed

Ljubljana, 20 December - Science Minister Igor Papič and Špela Miroševič, the head of a foundation developing a treatment for the the CTNNB1 syndrome, signed on Friday an agreement under which the state will co-fund pre-clinical and clinical studies for the gene therapy Urbagen, named after Miroševič's son Urban, who has the syndrome.

Ljubljana Špela Miroševič, the head of a foundation spearheading the development of a gene therapy for CTNNB1 (left), and Higher Education, Science and Innovation Minister Igor Papič (right) sign an agreement on state co-founding for pre-clinical and clinical trials for the therapy. Photo: Nebojša Tejić/STA

Ljubljana
Špela Miroševič, the head of a foundation spearheading the development of a gene therapy for CTNNB1 (left), and Higher Education, Science and Innovation Minister Igor Papič (right) sign an agreement on state co-founding for pre-clinical and clinical trials for the therapy.
Photo: Nebojša Tejić/STA

Ljubljana Špela Miroševič, the head of a foundation spearheading the development of a gene therapy for CTNNB1 (left), and Higher Education, Science and Innovation Minister Igor Papič (right) sign an agreement on state co-founding for pre-clinical and clinical trials for the therapy. Photo: Nebojša Tejić/STA

Ljubljana
Špela Miroševič, the head of a foundation spearheading the development of a gene therapy for CTNNB1 (left), and Higher Education, Science and Innovation Minister Igor Papič (right) sign an agreement on state co-founding for pre-clinical and clinical trials for the therapy.
Photo: Nebojša Tejić/STA

Ljubljana Špela Miroševič, the head of a foundation spearheading the development of a gene therapy for CTNNB1 (left), and Higher Education, Science and Innovation Minister Igor Papič (right) sign an agreement on state co-founding for pre-clinical and clinical trials for the therapy. Photo: Nebojša Tejić/STA

Ljubljana
Špela Miroševič, the head of a foundation spearheading the development of a gene therapy for CTNNB1 (left), and Higher Education, Science and Innovation Minister Igor Papič (right) sign an agreement on state co-founding for pre-clinical and clinical trials for the therapy.
Photo: Nebojša Tejić/STA

Ljubljana Špela Miroševič, the head of a foundation spearheading the development of a gene therapy for CTNNB1 (right), and Higher Education, Science and Innovation Minister Igor Papič (left) sign an agreement on state co-founding for pre-clinical and clinical trials for the therapy. Photo: Nebojša Tejić/STA

Ljubljana
Špela Miroševič, the head of a foundation spearheading the development of a gene therapy for CTNNB1 (right), and Higher Education, Science and Innovation Minister Igor Papič (left) sign an agreement on state co-founding for pre-clinical and clinical trials for the therapy.
Photo: Nebojša Tejić/STA

Ljubljana Špela Miroševič, the head of a foundation spearheading the development of a gene therapy for CTNNB1 (left), and Higher Education, Science and Innovation Minister Igor Papič (right) sign an agreement on state co-founding for pre-clinical and clinical trials for the therapy. Photo: Nebojša Tejić/STA

Ljubljana
Špela Miroševič, the head of a foundation spearheading the development of a gene therapy for CTNNB1 (left), and Higher Education, Science and Innovation Minister Igor Papič (right) sign an agreement on state co-founding for pre-clinical and clinical trials for the therapy.
Photo: Nebojša Tejić/STA

The rest of this news item is available to subscribers.
The news item consists of 994 characters (without spaces) or 193 words words.

Buy the news item. Price: 2 tokens; on account: 0 tokens.

mas/mab
© STA, 2024